PAR-23-267: Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $295,924 to small businesses. Applications closed on December 9, 2025.
From the official notice on Grants.gov, last changed December 9, 2025. Checked November 7, 2026.
- Award ceiling$295,924
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU43 / U44
- Clinical trialsNot allowed
- Funded byNCATS
- Median yearly award$985,974
- Typical project length2 years
Projects funded under PAR-23-267 were run by National Center for Advancing Translational Sciences (NCATS, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-267 in the NIH Guide.
Key dates
| Posted | April 18, 2023 |
|---|---|
| Deadline | December 9, 2025 |
| Archived by Grants.gov | February 7, 2026 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $985,974; it allows up to $295,924 per award.
- Most of the program's money (82% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This FOA provides support using the SBIR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for this funding opportunity is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine.
Funded under PAR-23-267 so far
NIH funded 1 project under PAR-23-267 in fiscal 2026, at 1 institution. The median yearly award was $985,974.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Industrial production of milk extracellular vesicles for dual-use as a systemic radiotherapeutic medical countermeasure and cancer adjuvant therapy | The Tiny Cargo Company | 2026 | $985,974 |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-267 still open?
No. It closed on December 9, 2025.
Who can apply for Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)?
Closed December 9, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $295,924 each.
Who has been funded under PAR-23-267?
NIH RePORTER lists 1 project funded under PAR-23-267 in fiscal 2026, at 1 institution.
Who has won National Center for Advancing Translational Sciences grants before?
The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.
Similar open grants
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)